MiFID medicine may be poison for small firms, warns Nordea AM

The head of Nordea Asset Management says new rules targeting conflicts of interest in his industry are hurting smaller fund managers as they struggle to keep up with the demands.
Nils Bolmstrand Head of Nordea Asset Management is worried about smaller asset managers ability to pay for research after implementation of MIFID II.
Nils Bolmstrand Head of Nordea Asset Management is worried about smaller asset managers ability to pay for research after implementation of MIFID II.
Frances Schwartzkopff, Bloomberg News

Nils Bolmstrand, chief executive officer of Nordea Asset Management ­ a unit of Nordea Bank which oversees about USD 257 billion ­ says new industry rules may end up being a case of the medicine killing the patient.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now


Further reading